mAbs

Article	Citations
Characterization of anti-SARS-CoV-2 monoclonal antibodies focusing on antigen binding, neutralization, and FcγR activation via formation of immune complex	299
Seq2scFv: a toolkit for the comprehensive analysis of display libraries from long-read sequencing platforms	236
Development of a novel, high-throughput imaged capillary isoelectric focusing-Western method to characterize charge heterogeneity of monoclonal antibody heavy and light chains	139
A next-generation Fab library platform directly yielding drug-like antibodies with high affinity, diversity, and developability	116
In silico prediction of post-translational modifications in therapeutic antibodies	108
Biologics developability data analysis using hierarchical clustering accelerates candidate lead selection, optimization, and preformulation screening	92
Phenotypic whole-cell screening identifies a protective carbohydrate epitope on Klebsiella pneumoniae	79
CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma	75
Correction	73
Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties	66
Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries	66
An antibody developability triaging pipeline exploiting protein language models	63
A window into the human immune system: comprehensive characterization of the complexity of antibody complementary-determining regions in functional antibodies	60
Insight into the avidity–affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn	59
Application of quantitative protein mass spectrometric data in the early predictive analysis of membrane-bound target engagement by monoclonal antibodies	53
Correction	48
Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis	45
Selection of target-binding proteins from the information of weakly enriched phage display libraries by deep sequencing and machine learning	43
The proximity of the N- and C- termini of bovine knob domains enable engineering of target specificity into polypeptide chains	40
Correction	40
The emergence of cell-based protein arrays to test for polyspecific off-target binding of antibody therapeutics	40
Simultaneous affinity maturation and developability enhancement using natural liability-free CDRs	39
A mouse pancreatic organoid model to compare PD-L1 blocking antibodies	38
Predicting antibody binders and generating synthetic antibodies using deep learning	37
GlycoVHH: optimal sites for introducing N-glycans on the camelid VHH antibody scaffold and use for macrophage delivery	36

Breaking barriers in antibody discovery: harnessing divergent species for accessing difficult and conserved drug targets	36
The nonglycosylated variant in therapeutic monoclonal antibodies preferentially forms large aggregates under typical thermal stresses used in forced degradation studies	35
In-line product quality monitoring during biopharmaceutical manufacturing using computational Raman spectroscopy	35
Mitochondrial membrane potential-enriched CHO host: a novel and powerful tool for improving biomanufacturing capability	34
Identification of tyrosine sulfation in the variable region of a bispecific antibody and its effect on stability and biological activity	33
Impact of IgG subclass on monoclonal antibody developability	32
Structural and functional characterization of a monoclonal antibody blocking TIGIT	31
Navigating large-volume subcutaneous injections of biopharmaceuticals: a systematic review of clinical pipelines and approved products	30
Unambiguous identification of α-Gal epitopes in intact monoclonal antibodies by NMR spectroscopy	30
Antibodies to watch in 2024	30
Effect of molecular size on interstitial pharmacokinetics and tissue catabolism of antibodies	30
Temperature and excipient mediated modulation of monoclonal antibody interactions revealed by k D, rheology, and Raman spectroscopy	28
T cell margination: investigating the detour of T cells following forimtamig treatment in humanized mice	27
Discovery of broadly neutralizing V H Hs against short-chain α-neurotoxins using a consensus toxin as an antigen	27
Targeted protein degradation through site-specific antibody conjugation with mannose 6-phosphate glycan	25
Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19	25
Physiochemical and functional evaluation of the first-in-class anti-cancer IgE antibody drug, MOv18, through process development and good manufacturing practice production	25
Decoding the mannose receptor-mAb interaction: the importance of high-mannose N-glycans and glycan-pairing	24
Sequence-based engineering of pH-sensitive antibodies for tumor targeting or endosomal recycling applications	23
Higher order receptor clustering due to the IgG3 subclass is necessary for TLR4 signaling and tolerance induction by novel human anti-TLR4 antibodies	22
Quantifying antibody binding: techniques and therapeutic implications	22
Separating clinical antibodies from repertoire antibodies, a path to in silico developability assessment	22
Epitope mapping of anti-drug antibodies to a clinical candidate bispecific antibody	22
Variable domain mutational analysis to probe the molecular mechanisms of high viscosity of an IgG 1 antibody	22
In silico proof of principle of machine learning-based antibody design at unconstrained scale	21
Comprehensive characterization of higher order structure changes in methionine oxidized monoclonal antibodies via NMR chemometric analysis and biophysical approaches	21
Bivalent non-human gal-α1-3-gal glycan epitopes in the Fc region of a monoclonal antibody model can be recognized by anti-Gal-α1-3-Gal IgE antibodies	21
Rapid affinity-based purification of multi-specific antibodies using Kappa Select and Protein L	21
Developability profiling of a panel of Fc engineered SARS-CoV-2 neutralizing antibodies	20
Analytical development and application of a targeted liquid chromatography-tandem mass spectrometry assay for chimeric aducanumab	19
Cost and supply considerations for antibody therapeutics	19
The eIg technology to generate Ig-like bispecific antibodies	18
IL-38 blockade induces anti-tumor immunity by abrogating tumor-mediated suppression of early immune activation	18
Modifying antibody-FcRn interactions to increase the transport of antibodies through the blood-brain barrier	18
Building a potent TREM2 agonistic, biparatopic, common light chain antibody	18
Evolution of phage display libraries for therapeutic antibody discovery	18
A glyco-engineering approach for site-specific conjugation to Fab glycans	18
RUBY® – a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties	17
Electrostatic properties of human germlines and biodistribution of small biologics	17
A versatile design platform for glycoengineering therapeutic antibodies	17
Antigenic landscapes on Staphylococcus aureus pore-forming toxins reveal insights into specificity and cross-neutralization	17
Hybrid IgE-IgG1 antibodies (IgEG): a new antibody class that combines IgE and IgG functionality	16
Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics	16
Improving the integrity and reproducibility of research that uses antibodies: a technical, data sharing, behavioral and policy challenge	16
Improved antibody pharmacokinetics by disruption of contiguous positive surface potential and charge reduction using alternate human framework	16
Deciphering deamidation and isomerization in therapeutic proteins: Effect of neighboring residue	16
A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations	16
Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity	15
Leveraging multi-modal feature learning for predictions of antibody viscosity	15
Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG 1 antibodies	15

Humatch - fast, gene-specific joint humanisation of antibody heavy and light chains	15
Engineering death resistance in CHO cells for improved perfusion culture	15
Efficient production of bispecific antibody by FAST-Ig TM and its application to NXT007 for the treatment of hemophilia A	15
Toward generalizable prediction of antibody thermostability using machine learning on sequence and structure features	14
Translational minimal physiologically based pharmacokinetic model for transferrin receptor-mediated brain delivery of antibodies	14
Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays	14
Predicting the clinical subcutaneous absorption rate constant of monoclonal antibodies using only the primary sequence: a machine learning approach	14
International nonproprietary names for monoclonal antibodies: an evolving nomenclature system	14
Reduction of monoclonal antibody viscosity using interpretable machine learning	14
Structural and biochemical differences between non-catalytic and catalytic antibodies	14
Predicting purification process fit of monoclonal antibodies using machine learning	14
Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows	14
Non-targeted characterization of attributes affecting antibody-FcγRIIIa V158 (CD16a) binding via online affinity chromatography-mass spectrometry	13
Full-length recombinant antibodies from Escherichia coli : production, characterization, effector function (Fc) engineering, and clinical evaluation	13
Coactivation of Tie2 and Wnt signaling using an antibody–R-spondin fusion potentiates therapeutic angiogenesis and vessel stabilization in hindlimb ischemia	13
Therapeutic efficacy of a potent anti-Venezuelan equine encephalitis virus antibody is contingent on Fc effector function	13
With great power, comes great responsibility: the importance of broadly measuring Fc-mediated effector function early in the antibody development process	13
A novel anti-NGF PEGylated Fab’ provides analgesia with lower risk of adverse effects	12
Combining deep mutational scanning and SPR binning approaches for large-scale epitope identification of anti-ricin antibodies	12
A machine learning strategy for the identification of key in silico descriptors and prediction models for IgG monoclonal antibody developability properties	12
Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?	12
Development of QSAR models for in silico screening of antibody solubility	12
Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1	12
Identification of novel anti-CD16a antibody clones for the development of effective natural killer cell engagers	12
Facilitating high throughput bispecific antibody production and potential applications within biopharmaceutical discovery workflows	11
Discovery and characterization of a monoclonal antibody targeting a conformational epitope of IL-6/IL-6Rα to inhibit IL-6/ IL-6Rα /gp130 hexameric signaling complex formation	11
Illuminating a biologics development challenge: systematic characterization of CHO cell-derived hydrolases identified in monoclonal antibody formulations	11
Correction	11
Determination of ultra-trace metal-protein interactions in co-formulated monoclonal antibody drug product by SEC-ICP-MS	11
Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptors	11
NAb-seq: an accurate, rapid, and cost-effective method for antibody long-read sequencing in hybridoma cell lines and single B cells	11
Antibody markup language (AbML) — a notation language for antibody-based drug formats and software for creating and rendering AbML (abYdraw)	11
Understanding the structure–property relationship of bispecific monoclonal antibodies with Fc site-specific substitutions	11
Upstream cell culture process characterization and in-process control strategy development at pandemic speed	11
The impact of forced degradation conditions on mAb dimer formation and subsequent influence on aggregation propensity	11
Identification and characterization of an unexpected isomerization motif in CDRH2 that affects antibody activity	10
Prediction of protein biophysical traits from limited data: a case study on nanobody thermostability through NanoMelt	10
A library approach for the de novo high-throughput isolation of humanized VHH domains with favorable developability properties following camelid immunization	10
An adapted consensus protein design strategy for identifying globally optimal biotherapeutics	10
Targeted fusion of antibody-secreting cells: Unlocking monoclonal antibody production with hybridoma technology	10
Early determination of potential critical quality attributes of therapeutic antibodies in developability studies through surface plasmon resonance-based relative binding activity assessment	10
Liposomal T cell engager and re-director for tumor cell eradication in cancer immunotherapy	10
Generation of a novel fully human non-superagonistic anti-CD28 antibody with efficient and safe T-cell co-stimulation properties	10
Affinity-controlled capture and release of engineered monoclonal antibodies by macroporous dextran hydrogels using coiled-coil interactions	9
High-throughput profiling of antibody self-association in multiple formulation conditions by PEG stabilized self-interaction nanoparticle spectroscopy	9
BioPhi: A platform for antibody design, humanization, and humanness evaluation based on natural antibody repertoires and deep learning	9
Modulation of the high concentration viscosity of IgG 1 antibodies using clinically validated Fc mutations	9
Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studies	9
Computational models for studying physical instabilities in high concentration biotherapeutic formulations	9
IL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+ T cells to induce potent anti-cancer cytotoxic activity with limited cytokine releas	9
Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions	9
BERT2DAb: a pre-trained model for antibody representation based on amino acid sequences and 2D-structure	9
Epitope mapping of monoclonal antibodies: a comprehensive comparison of different technologies	9
Computational design of therapeutic antibodies with improved developability: efficient traversal of binder landscapes and rescue of escape mutations	9
Suitability of transiently expressed antibodies for clinical studies: product quality consistency at different production scales	9
Development of potent humanized TNFα inhibitory nanobodies for therapeutic applications in TNFα-mediated diseases	9
Determining the affinities of high-affinity antibodies using KinExA and surface plasmon resonance	9
Accelerating high-concentration monoclonal antibody development with large-scale viscosity data and ensemble deep learning	8
Analysis of how antigen mutations disrupt antibody binding interactions toward enabling rapid and reliable antibody repurposing	8
Physicochemical and biological impact of metal-catalyzed oxidation of IgG1 monoclonal antibodies and antibody-drug conjugates via reactive oxygen species	8
Correction	8
Development of T-cell engagers selective for cells co-expressing two antigens	8
FcRn-enhancing mutations lead to increased and prolonged levels of the HIV CCR5-blocking monoclonal antibody leronlimab in the fetuses and newborns of pregnant rhesus macaques	8
Proceedings of the 15 th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals	8
Targeted chain-exchange-mediated reconstitution of a split type-I cytokine for conditional immunotherapy	8
Folate receptor alpha for cancer therapy: an antibody and antibody-drug conjugate target coming of age	8
Achieving Acceleration to First-in-Human: MSD’s Learnings on Platform Method Validation Strategy	8
Development of novel ultra-sensitive IL-11 target engagement assays to support mechanistic PK/PD modeling for an anti-IL-11 antibody therapeutic	8
Characterization of free light chain impurity in a bispecific antibody	7
A bispecific antibody-drug conjugate targeting pCAD and CDH17 has antitumor activity and improved tumor-specificity	7
Systematic analysis of Fc mutations designed to enhance binding to Fc-gamma receptors	7
Generation and engineering of potent single domain antibody-based bispecific IL-18 mimetics resistant to IL-18BP decoy receptor inhibition	7
Successful targeting of multidrug-resistant tumors with bispecific antibodies	7
Molecular recognition requires dimerization of a VHH antibody	7
Large-scale data mining of four billion human antibody variable regions reveals convergence between therapeutic and natural antibodies that constrains search space for biologics drug discovery	7
Characterization of high-molecular weight by-products in the production of a trivalent bispecific 2+1 heterodimeric antibody	7
Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors	7
Process development for production of non-originator NISTmAb from CHO and NS0 cell lines	7
The history and potential future of monoclonal antibody therapeutics development and manufacturing in four eras	7
Systematic analysis of Fc mutations designed to reduce binding to Fc-gamma receptors	7

A novel in vitro serum stability assay for antibody therapeutics incorporating internal standards	6
Enhanced immunogenic potential of cancer immunotherapy antibodies in human IgG1 transgenic mice	6
Use of poxvirus display to select antibodies specific for complex membrane antigens	6
YAbS: The Antibody Society’s antibody therapeutics database	6
Delivery of the Brainshuttle™ amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans	6
Interplay of heavy chain introns influences efficient transcript splicing and affects product quality of recombinant biotherapeutic antibodies from CHO cells	6
Recommended nomenclature convention for the NISTCHO cell line and its product monoclonal antibody, cNISTmAb	6
Strategies for clinical dose optimization of T cell-engaging therapies in oncology	6
The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy	6
Discovery and characterization of prolactin neutralizing monoclonal antibodies for the treatment of female-prevalent pain disorders	6
Fast-tracking antibody maturation using a B cell-based display system	6
Correction	6
In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies	6
Structure-based engineering of a novel CD3ε-targeting antibody for reduced polyreactivity	6
Developing drug-like single-domain antibodies (VHH) from in vitro libraries	5
Homogeneous antibody-drug conjugates with dual payloads: potential, methods and considerations	5
Innovative strategies for T cell engagers for cancer immunotherapy	5
Deciphering cross-species reactivity of LAMP-1 antibodies using deep mutational epitope mapping and AlphaFold	5
Design of orthogonal constant domain interfaces to aid proper heavy/light chain pairing of bispecific antibodies	5
A bispecific antibody–drug conjugate targeting CD7 and CD33 shows anti-tumor activity and improved tumor selectivity in an aggressive subtype of acute myeloid leukemia	5
Discovery and engineering of an anti-TREM2 antibody to promote amyloid plaque clearance by microglia in 5XFAD mice	5
Data-driven analyses of human antibody variable domain germlines: pairings, sequences and structural features	5
Optimizing asymmetric antibody purification: a semi-automated process and its digital integration	5
Improved pharmacokinetics of HIV-neutralizing VRC01-class antibodies achieved by reduction of net positive charge on variable domain	5
Non-human primates in the PKPD evaluation of biologics: Needs and options to reduce, refine, and replace. A BioSafe White Paper	5
Discovery of a novel highly specific, fully human PSCA antibody and its application as an antibody-drug conjugate in prostate cancer	4
Mechanistic insights into the rational design of masked antibodies	4
Correlated analytical and functional evaluation of higher order structure perturbations from oxidation of NISTmAb	4
Trispecific SEED antibodies engineered for neutrophil-mediated cell killing	4
Biophysical characterization of PVR family interactions and therapeutic antibody recognition to TIGIT	4
Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies	4
Comprehensive engineering of a therapeutic neutralizing antibody targeting SARS-CoV-2 spike protein to neutralize escape variants	4
GB18-06, a nanobody targeting GDF15, effectively alleviates weight loss and restores physical function in cachexia models	4
How to think about designing smart antibodies in the age of genAI: integrating biology, technology, and experience	4
Generation of robust bispecific antibodies through fusion of single-domain antibodies on IgG scaffolds: a comprehensive comparison of formats	4
TRYBE®: an Fc-free antibody format with three monovalent targeting arms engineered for long in vivo half-life	4
“Stapling” scFv for multispecific biotherapeutics of superior properties	4
Residue-resolved insights into the stabilization of therapeutic proteins by excipients: A case study of two monoclonal antibodies with arginine and glutamate	4
Characterization of the bispecific VHH antibody tarperprumig (ALXN1820) specific for properdin and designed for low-volume administration	4
Elimination of plasma soluble antigen in cynomolgus monkeys by combining pH-dependent antigen binding and novel Fc engineering	4
A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer	4
Engineering hydrophobicity and manufacturability for optimized biparatopic antibody–drug conjugates targeting c-MET	4
A perspective toward mass spectrometry-based de novo sequencing of endogenous antibodies	4
A competitive binding-mass spectrometry strategy for high-throughput evaluation of potential critical quality attributes of therapeutic monoclonal antibodies	4
Selection of bispecific antibodies with optimal developability using FcRn‑pH‑HPLC as an optimized FcRn affinity chromatography method	4
HDX-MS study on garadacimab binding to activated FXII reveals potential binding interfaces through differential solvent exposure	4
Expanding the structural resolution of glycosylation microheterogeneity in therapeutic proteins by salt-free hydrophilic interaction liquid chromatography tandem mass spectrometry	4
Biparatopic binding of ISB 1442 to CD38 in trans enables increased cell antibody density and increased avidity	4